Anticoagulation in the Elderly

  • Ruchika Harisingani
  • Ibrahim M. Ali
  • Bhakti Shah
  • Salonie Pereira
Chapter

Abstract

With an aging population comes an increasing prevalence of cardiovascular diseases such as atrial fibrillation and coronary artery disease. Anticoagulation is a cornerstone of therapy to prevent stroke in patients with atrial fibrillation. Antiplatelet therapy is essential for the primary and secondary prevention of ischemic heart disease. Since anticoagulants and antiplatelet agents are associated with increased risks of bleeding, it is important for clinicians to weigh the risks and benefits of these medications in the elderly. In this chapter, we review the age-associated changes in drug metabolism via three clinical scenarios commonly encountered in the management of anticoagulation therapy in the geriatric patient:
  • Use of direct oral anticoagulants in the elderly

  • Risk of intracranial bleeding in the elderly

  • An elderly patient on triple therapy (warfarin, aspirin, clopidogrel)

We also briefly discuss the topics of discontinuing these agents when clinically appropriate and the non-pharmacological management of atrial fibrillation.

Keywords

Elderly Anticoagulation Atrial fibrillation Coronary heart disease Bleeding Falls Direct oral anticoagulants 

References

  1. 1.
    Capodanno D, Angiolillo D. Antithrombotic therapy in the elderly. J Am Coll Cardiol. 2010;56:1683–92.CrossRefGoogle Scholar
  2. 2.
    Myat A, Yousif A, Shouvik H, et al. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Rev Cardiovasc Ther. 2013;11(8):1029–49.CrossRefGoogle Scholar
  3. 3.
    Gurwitz J. Warfarin in complex older patients: have we reached a tipping point? JAGS. 2017;65:236–7.CrossRefGoogle Scholar
  4. 4.
    McGrath ER, Go AS, Chang Y, et al. Use of oral anticoagulant therapy in older adults with atrial fibrillation after acute ischemic stroke. JAGS. 2017;65:241–8.CrossRefGoogle Scholar
  5. 5.
    Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285(18):2370–5.CrossRefGoogle Scholar
  6. 6.
    Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123:484–8.CrossRefGoogle Scholar
  7. 7.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22:983–8.CrossRefGoogle Scholar
  8. 8.
    Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HASBLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126(7):860–5.CrossRefGoogle Scholar
  9. 9.
    Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014;62(5):857–64.CrossRefGoogle Scholar
  10. 10.
    Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–64.CrossRefGoogle Scholar
  11. 11.
    Coppens M, Eikelboom J, Ezekowitz M, et al. Dabigatran versus warfarin in very elderly patients with atrial fibrillation: results from the RE-LY trail. Circulation. 2012;126:A151537.Google Scholar
  12. 12.
    Becattini C, Sembolini A, Paciaroni M. Resuming anticoagulant therapy after intracerebral bleeding. Vasc Pharmacol. 2016;84:15–24.CrossRefGoogle Scholar
  13. 13.
    Kearon C, Akl EA, Ornealas J, et al. Antithrombotic therapy for VTE disease: chest guidelines expert panel report. Chest. 2016;149(2):315–52.CrossRefGoogle Scholar
  14. 14.
    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRefGoogle Scholar
  15. 15.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(22):e57–185.CrossRefGoogle Scholar
  16. 16.
    Lopes RD, Guimaraes PO, Kolls BJ, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017;129(22):2980–7.CrossRefGoogle Scholar
  17. 17.
    Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013;35(3):312–9.CrossRefGoogle Scholar
  18. 18.
    Strate LL. Lower GI bleeding: epidemiology and diagnosis. Gastroenterol Clin North Am. 2005;34(4):643–64.CrossRefGoogle Scholar
  19. 19.
    Chatterjee S, Lip GY, Giri J. HAS-BLED versus ATRIA risk scores for intracranial hemorrhage in patients receiving thrombolytics for pulmonary embolism. J Am Coll Cardiol. 2016;67(24):2904–5.CrossRefGoogle Scholar
  20. 20.
    Appelboam R, Thomas EO. Warfarin and intracranial haemorrhage. Blood Rev. 2009;23(1):1–9.CrossRefGoogle Scholar
  21. 21.
    Jeffree R, Gordon DH, Sivasubramaniam R, Chapman A. Warfarin related intracranial haemorrhage: a case-controlled study of anticoagulation monitoring prior to spontaneous subdural or intracerebral haemorrhage. J Clin Neurosci. 2009;16(7):882–5.CrossRefGoogle Scholar
  22. 22.
    Hoffman E, Faller N, Limacher A. Educational level, anticoagulation quality, and clinical outcomes in elderly patients with acute venous thromboembolism: a prospective cohort study. PLoS One. 2016;11(9):e0162108.CrossRefGoogle Scholar
  23. 23.
    Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2(3):e000250.CrossRefGoogle Scholar
  24. 24.
    Kooistra HA, Calf AH, Piersma-Wichers M, et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica. 2006;91(8):1046–51.Google Scholar
  25. 25.
    Yasgur BS. Weighing benefits and risks of anticoagulation in the elderly. The cardiology advisor Oct 24, 2016. http://www.thecardiologyadvisor.com/stroke/anticogulation-stroke-prevention-in-elderly/article/567835/2/.
  26. 26.
    Ashburner JM, Go AS, Chang Y, et al. Influence of competing risks on the association between warfarin and ischemic stroke in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2015;132:A11900.Google Scholar
  27. 27.
    Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102:1618–23.CrossRefGoogle Scholar
  28. 28.
    Mehta SR on behalf of the CURRENT Steering Committee. A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: results of the CURRENT OASIS 7 Trial. Presented at: European Society of Cardiology Congress 2009; August 30, 2009; Barcelona, Spain. Presentation No. 177.Google Scholar
  29. 29.
    Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv. 2011;4:522–34.CrossRefGoogle Scholar
  30. 30.
    King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2005 Writing Committee Members. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee [published correction appears in Circulation. 2008; 117:e161]. Circulation. 2008;117:261–95.CrossRefGoogle Scholar
  31. 31.
    Dewilde W, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–15.CrossRefGoogle Scholar
  32. 32.
    Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713–8.CrossRefGoogle Scholar
  33. 33.
    Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155–79.CrossRefGoogle Scholar
  34. 34.
    Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981–9.CrossRefGoogle Scholar
  35. 35.
    Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139–228.CrossRefGoogle Scholar
  36. 36.
    Fiedler KA, Maeng M, Mehilli J, Schulz-Schüpke S, Byrne RA, Sibbing D, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65(16):1619–29.CrossRefGoogle Scholar
  37. 37.
    Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.CrossRefGoogle Scholar
  38. 38.
    Cannon CP, Gropper S, Bhatt DL, et al. RE-DUAL PCI steering committee and investigators. Design and rationale of the RE-DUAL PCI Trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin Cardiol. 2016;39(10):555–64.CrossRefGoogle Scholar
  39. 39.
    Hess CN, Peterson ED, Peng SA, et al. Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation. J Am Coll Cardiol. 2015;66:616–27.CrossRefGoogle Scholar
  40. 40.
    Buresly K, Eisenberg MJ, Zhang X, et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med. 2005;165(7):784–9.CrossRefGoogle Scholar
  41. 41.
    Sellers MB, Newby KL. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161(2):241–6.CrossRefGoogle Scholar
  42. 42.
    Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677–85.CrossRefGoogle Scholar
  43. 43.
    Sorensen R, Hansen ML. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–74.CrossRefGoogle Scholar
  44. 44.
    Steinberg B, Greiner M, Hammill B, et al. Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. Cardiovasc Ther. 2015;33(4):177–83.CrossRefGoogle Scholar
  45. 45.
    Hsu JC, Maddox TM, Kennedy K, et al. Aspirin is being used instead of oral anticoagulation in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol. 2016;67(925):2913–23.CrossRefGoogle Scholar
  46. 46.
    Gordon SF, Dainty C, Smith T. Why and when to withdraw drugs in the elderly and frail. Prescriber. 2012;23:47–51.CrossRefGoogle Scholar
  47. 47.
    Pharmacist’s letter/Prescriber’s letter September 2011.Google Scholar
  48. 48.
    Piccini JP, Horst S, Patel M. Left atrial appendage occlusion: rationale, evidence, devices, and patient selection. Eur Heart J. 2016;38(12):869–76.Google Scholar
  49. 49.
    Karamichalakis N, Letsas K, Vlachos K, et al. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag. 2015;11:555–62.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Khaji A, Kowey PR. Update on atrial fibrillation. Trends Cardiovasc Med. 2016;27(1):14–25.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ruchika Harisingani
    • 1
  • Ibrahim M. Ali
    • 2
  • Bhakti Shah
    • 1
  • Salonie Pereira
    • 1
  1. 1.Department of MedicineNorthwell Health, Zucker School of Medicine at Hofstra/NorthwellManhassetUSA
  2. 2.Department of CardiologyNorthwell Health, Zucker School of Medicine at Hofstra/NorthwellManhassetUSA

Personalised recommendations